Drug Profile
MDL 19347
Latest Information Update: 15 Sep 2004
Price :
$50
*
At a glance
- Originator Aventis
- Class
- Mechanism of Action Steroid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 27 Oct 2003 Discontinued - Preclinical for Hypertension in USA (unspecified route)